Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Biomimetic Platelet-Cloaked Nanoparticles for the Delivery of Anti-Inflammatory Curcumin in the Treatment of Atherosclerosis.

Flavia Fontana | Giuseppina Molinaro | Sofia Moroni | Giulia Pallozzi | Mónica P A Ferreira | Rubén Pareja Tello | Khalil Elbadri | Giulia Torrieri | Alexandra Correia | Marianna Kemell | Luca Casettari | Christian Celia | Hélder A Santos
Advanced healthcare materials | 2024

Atherosclerosis still represents a major driver of cardiovascular diseases worldwide. Together with accumulation of lipids in the plaque, inflammation is recognized as one of the key players in the formation and development of atherosclerotic plaque. Systemic anti-inflammatory treatments are successful in reducing the disease burden, but are correlated with severe side effects, underlining the need for targeted formulations. In this work, curcumin is chosen as the anti-inflammatory payload model and further loaded in lignin-based nanoparticles (NPs). The NPs are then coated with a tannic acid (TA)- Fe (III) complex and further cloaked with fragments derived from platelet cell membrane, yielding NPs with homogenous size. The two coatings increase the interaction between the NPs and cells, both endothelial and macrophages, in steady state or inflamed status. Furthermore, NPs are cytocompatible toward endothelial, smooth muscle and immune cells, while not inducing immune activation. The anti-inflammatory efficacy is demonstrated in endothelial cells by real-time quantitative polymerase chain reaction and ELISA assay where curcumin-loaded NPs decrease the expression of Nf-κb, TGF-β1, IL-6, and IL-1β in lipopolysaccharide-inflamed cells. Overall, due to the increase in the cell-NP interactions and the anti-inflammatory efficacy, these NPs represent potential candidates for the targeted anti-inflammatory treatment of atherosclerosis.

Pubmed ID: 38499190

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: UMCG Research Funds,
  • Agency: European Union - NextGenerationEU - under the Italian Ministry of University and Research (MUR),
    Id: ECS00000041-VITALITY-CUP [H33C2200043006]
  • Agency: H2020 Marie Skłodowska-Curie Actions,
    Id: 955685
  • Agency: H2020 European Research Council,
    Id: 825020
  • Agency: Business Finland,
    Id: 1179/31/2020
  • Agency: Luonnontieteiden ja Tekniikan Tutkimuksen Toimikunta,
    Id: 331151
  • Agency: Erasmus+,

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.